Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This phase II study assessed the efficacy and toxicity of an intermittent weekly capecitabine regimen in combination with oxaliplatin (XELOX) plus bevacizumab as a first-line treatment of metastatic colorectal cancer (mCRC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Anticancer Res.

Title: Anticancer research

ISSN (Electronic): 1791-7530

ISSN (Print): 0250-7005

Publication date (Electronic): Jul 2016

Volume: 36

Issue: 7

Affiliations

[1 ] Surgery, Aichi cancer center, Aichi Hospital, Kuriyado Kakemachi, Okazaki City, Japan.

[2 ] Kitakyushu General Hospital, Kitakyushu, Japan n-nagata@kitakyu-hp.or.jp.

[3 ] Department of Surgery 1, University of Occupational and Environmental Health, Fukuoka, Japan.

[4 ] Department of Surgery, Kori Hospital, Kansai Medical University, Osaka, Japan.

[5 ] Department of General and Gastroenterological Surgery, Fujigaoka Hospital, Showa University, Yokohama, Japan.

[6 ] Cancer Center, Aizawa Hospital, Matsumoto, Japan.

[7 ] Department of Surgery, Osaka Rosai Hospital, Osaka, Japan.

[8 ] Translational Research and Clinical Trial Center, Hokkaido University Hospital, Sapporo, Japan.

[9 ] Tokaki Central Hospital, Kamigahara City, Japan.

[10 ] Oncology Center, Aichi Medical University Hospital, Aichi, Japan.

Article

Publisher Item ID: 36/7/3437

PubMed ID: 27354605

SO-VID: aba46bba-8b98-40a8-9afc-d49a03ba457e

History

Keywords: bi-weekly,phase II study,bevacizumab,XELOX,Chemotherapy

Data availability:

Keywords: bi-weekly, phase II study, bevacizumab, XELOX, Chemotherapy

Comments

Comment on this article

Cited by 4

See all cited by